2018 American Transplant Congress
Deceased Donor Urinary Biomarker Signature and the Effectiveness of Peritransplant Lymphocyte Depletion on Early Renal Allograft Function
Purpose: Delayed graft function (DGF) is associated with increased allogaft immunogenicity and decreased long-term survival. We hypothesized that high levels of donor urinary biomarkers for…2018 American Transplant Congress
Differences in Rejection and Clinical Outcomes in Obese versus Non-Obese Renal Transplant Recipients Receiving Basiliximab Induction Immunosuppression
Introduction: Basilixiab is a fixed-dose IL-2 receptor antagonist that is used for non-lymphodepleting induction therapy. The impact of obesity on basiliximab pharmacokinetics and pharmacodynamics is…2018 American Transplant Congress
Single Reduced Dose Thymoglobuline as Induction in Kidney Retransplant
Hospital do Rim, São Paulo, Brazil.
IntroductionKidney retransplant is a high risk procedure, without a consensus about the best induction imunnossupression strategy. Only a few studies have evaluated these growing proportion…2018 American Transplant Congress
Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort
Purpose: There is an elevated risk of acute rejection in HIV+ renal transplant recipients and continued evaluation of the most appropriate induction therapy remains. Use…2018 American Transplant Congress
A Meta-Analysis for Induction Therapy of Kidney Transplantation: Comparison of Antithymocyte Globulin and Interleukin 2 Receptor Antagonist
Objectives To compare the efficacy and safety of antithymocyte globulin (ATG) and interleukin 2 receptor antagonist (IL2Ra) in induction therapy of kidney transplantation.Method A literature…2018 American Transplant Congress
Improved Value with Individualized Antithymocyte Globulin Dosing Protocol in Renal Transplant
University of Virginia Healthsystem, Charlottesville, VA.
Medication costs represent one of the largest costs associated with transplantation. With growing pressure to reduce health care costs while maintaining excellent outcomes, this study…2017 American Transplant Congress
BK Polyoma Virus and Malignancy: Cause or Co-Incidence?
Henry Ford Transplant Institute, Detroit, MI
BackgroundThe WHO agency for cancer research has classified BKV as "possibly carcinogenic".The etiological role of BKV in human cancer, however,remains controversial.We present 5 cases of…2017 American Transplant Congress
Three Induction Therapies on Patients with Delayed Graft Function After Kidney Transplantation, a Three-Year Outcome Analysis.
Departments of Medicine and Surgery, Tulane University School of Medicine, New Orleans, LA
We compare the 3-year outcomes of induction therapies with either methylprednisolone (group 1, n=58), basiliximab (group 2, n=56) or alemtuzumab (group 3, n=98) in primary…2017 American Transplant Congress
The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.
University of Maryland Medical Center, Baltimore, MD
Background: Renal transplant recipients (RTRs) with HCV are at an increased risk of graft rejection, making treatment of HCV in this population of the utmost…2017 American Transplant Congress
Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).
Growing evidence implicates B cells in transplant tolerance. RESTARRT is a 6-center ISW study in adult living-related-donor KTR receiving ATG induction and rituximab with a…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 31
- Next Page »